Orbimed Advisors LLC and Orbimed Capital Gp IX LLC Buys $20M of Windward BIO Group Ag (WWB) — SEC Form 4, Nov 18, 2026
Open-Market Net Purchase · SEC Form 4
+$20,000,007
Equity position changed by +1234.5%
Reporting Owners
Director
10% Owner
Director
10% Owner
TXN 2026-11-16
·
FILED 2026-11-18
Equity Position
7.1M sh
531,864 → 7,097,715
Equity Change
+1234.5%
shares held after vs before
Insider Cluster
4 buying
within 30 days — view cluster
Filing Lag
2 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owners
| Name | Relationship |
|---|---|
| Orbimed Advisors LLC CIK 0001055951 |
Director
10% Owner
|
| Orbimed Capital Gp IX LLC CIK 0001920574 |
Director
10% Owner
|
Orbimed Advisors LLC at Windward BIO Group Ag
Full insider history
Bought (12 mo)
$20,000,007
Sold (12 mo)
—
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common SharesF1F2F3 | 2026-11-16 | P - Purchase | 1,176,471 A | $17.00 | +$20,000,007 | 1,708,103 | Indirect See footnotes |
| Common SharesF4F2F3 | 2026-11-16 | C - Conversion | 3,561,936 A | — | 5,270,039 | Indirect See footnotes | |
| Common SharesF4F2F3 | 2026-11-16 | C - Conversion | 1,611,008 A | — | 6,881,047 | Indirect See footnotes | |
| Common SharesF5F2F3 | 2026-11-16 | M - Exercise | 216,668 A | $0.02 | +$4,333 | 7,097,715 | Indirect See footnotes |
| Common SharesF6F2F3 | 2026-11-16 | F - Tax Payment | 232 D | $17.00 | -$3,944 | 7,097,483 | Indirect See footnotes |
Derivative Securities Transactions
| Title | Strike | Date | Type | Shares | Price | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| Series A Preferred SharesF4F4F4F2F3 | 2026-11-16 | C - Conversion | 3,561,936 D | $0.00 | 3,561,936 Common Shares | Indirect See footnotes | ||
| Series B Preferred SharesF4F4F4F2F3 | 2026-11-16 | C - Conversion | 1,611,008 D | $0.00 | 1,611,008 Common Shares | Indirect See footnotes | ||
| Warrants (right to buy)F5F7F2F3 | $0.02 | 2026-11-16 | M - Exercise | 216,668 D | $0.00 | 2036-05-12 | 216,668 Common Shares | Indirect See footnotes |
Footnotes (7)
- F1
- Reflects Common Shares of the Issuer purchased in the Issuer's initial public offering. Show more
- F2
- These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX. Show more
- F3
- This report on Form 4 is jointly filed by OrbiMed Advisors and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose. Show more
- F4
- Each Series A Preferred Share and Series B Preferred Share automatically converted into the number of Common Shares on a 1-to-1 basis immediately prior to the closing of the Issuer's initial public offering and has no expiration date. Show more
- F5
- The exercise price is in US Dollars and reflects the conversion of CHF to USD at an exchange rate of $1.2151 to CHF 1.00 as of October 30, 2026, as approved by the Issuer's board of directors. Show more
- F6
- Reflects Common Shares withheld in connection with the Reporting Person's exercise of warrants. Show more
- F7
- The warrants are fully vested and exercisable. Show more
Related filings at Windward BIO Group Ag
Other insiders at Windward BIO Group Ag
GET /v1/forms/4/0000947871-26-001038
API docs
View Original SEC Filing